Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk

Prostate Cancer and Prostatic Diseases volume 7, pages 333–337 (2004)Cite this article

Abstract

Polymorphism of the steroid hormone-related genes might affect life-long androgen exposure, thus altering a risk of prostate cancer incidence. To evaluate the effect of the polymorphisms of CYP17 and SRD5A2 on serum steroid hormone levels, the 164 male Japanese cohort were tested for serum hormone levels and the genotype of the polymorphisms of CYP17 (T–C base substitution in the promoter region) and SRD5A2 (V89L). The linear trends across the CYP17 genotypes in serum-free testosterone and androstenedione levels were found, suggesting the importance of the polymorphism of CYP17 in determining the circulating androgen levels.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Landis SH, Murray T, Bolden S, Wingo PA . Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6–29.

    Article  CAS  Google Scholar 

  2. Landis SH, Murray T, Bolden S, Wingo PA . Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8–31.

    Article  CAS  Google Scholar 

  3. Ross R et al. Serum testosterone levels in healthy young black and white men 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. J Natl Cancer Inst 1986; 76: 45–48.

    CAS  PubMed  Google Scholar 

  4. Ross RK et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887–889.

    Article  CAS  Google Scholar 

  5. de Jong FH et al. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch–Japanese case–control study. Cancer Res 1991; 51: 3445–3450.

    CAS  PubMed  Google Scholar 

  6. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS . Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000; 18: 847–853.

    Article  CAS  Google Scholar 

  7. Lunn RM, Bell DA, Mohler JL, Taylor JA . Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999; 20: 1727–1731.

    Article  CAS  Google Scholar 

  8. Gsur A et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000; 87: 434–437.

    Article  CAS  Google Scholar 

  9. Wadelius M et al. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999; 9: 635–639.

    CAS  PubMed  Google Scholar 

  10. Haiman CA et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 743–748.

    CAS  PubMed  Google Scholar 

  11. Habuchi T et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000; 60: 5710–5713.

    CAS  PubMed  Google Scholar 

  12. Febbo PG et al. The V89L polymorphism in the 5 alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res 1999; 59: 5878–5881.

    CAS  PubMed  Google Scholar 

  13. Nam RK et al. V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 2001; 57: 199–204.

    Article  CAS  Google Scholar 

  14. Hsing AW et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2001; 10: 1077–1082.

    CAS  PubMed  Google Scholar 

  15. Makridakis N et al. A prevalent missense substitution that modulates activity of prostatic steroid 5 alpha-reductase. Cancer Res 1997; 57: 1020–1022.

    CAS  Google Scholar 

  16. Li Z et al. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J Urol 2003; 169: 2378–2381.

    Article  CAS  Google Scholar 

  17. Carey AH et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3: 1873–1876.

    Article  CAS  Google Scholar 

  18. Feigelson HS et al. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998; 58: 585–587.

    CAS  PubMed  Google Scholar 

  19. Haiman CA et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999; 59: 1015–1020.

    CAS  PubMed  Google Scholar 

  20. Ye Z, Parry JM . The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 2002; 17: 119–126.

    Article  CAS  Google Scholar 

  21. Feigelson HS et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Cancer Res 1997; 57: 1063–1065.

    CAS  PubMed  Google Scholar 

  22. Allen NE, Forrest MS, Key TJ . The association between polymorphisms in the CYP17 and 5 alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev 2001; 10: 185–189.

    CAS  PubMed  Google Scholar 

  23. Walsh PC, Wilson JD . The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 1976; 57: 1093–1097.

    Article  CAS  Google Scholar 

  24. Gann PH et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 1118–1126.

    Article  CAS  Google Scholar 

  25. Vermeulen A, Verdonck G . Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab 1992; 74: 939–942.

    Article  CAS  Google Scholar 

  26. Makridakis NM, di Salle E, Reichardt JK . Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 2000; 10: 407–413.

    Article  CAS  Google Scholar 

  27. Ross RK, Henderson BE . Do diet and androgens alter prostate cancer risk via a common etiologic pathway? J Natl Cancer Inst 1994; 86: 252–254.

    Article  CAS  Google Scholar 

  28. Oishi K, Yoshida O, Schroeder FH . The geography of prostate cancer and its treatment in Japan. Cancer Surv 1995; 23: 267–280.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Akita University School of Medicine, Akita, Japan

    H Kakinuma, N Tsuchiya, T Habuchi, C Ohyama, S Matsuura, L Wang & T Kato

  2. Department of Medical Information Science, Akita University School of Medicine, Akita, Japan

    A Nakamura

Authors
  1. H Kakinuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Habuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Ohyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Matsuura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Habuchi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kakinuma, H., Tsuchiya, N., Habuchi, T. et al. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk. Prostate Cancer Prostatic Dis 7, 333–337 (2004). https://doi.org/10.1038/sj.pcan.4500753

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500753

Keywords

This article is cited by

Search

Advanced search

Quick links